ClinicalTrials.govpublic full text
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
systemic sclerosis, pirfenidone, ssc-ild, scleroderma, interstitial lung disease, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 887448
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.